Active, not recruitingInterventional · Phase 2/3NCT02339571 ↗Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Active, not recruitingInterventional · Phase 1NCT02886065 ↗A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple MyelomaRuben NiesvizkyPIInterventionDrug: Hiltonol · Drug: Citarinostat · Drug: Lenalidomide · Biological: PVX-410DatesMar 2017 – Feb 2027 (est.)SponsorDana-Farber Cancer InstituteSmoldering Multiple Myeloma
Active, not recruitingInterventional · Phase 3NCT02954874 ↗A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant ChemotherapyEleni AndreopoulouPIInterventionProcedure: Biospecimen Collection · Other: Laboratory Biomarker Analysis · Other: Patient Observation · Biological: Pembrolizumab · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation TherapyDatesJan 2017 – Aug 2026SponsorSouthwest Oncology GroupBreast Carcinoma In SituInvasive Breast CarcinomaStage I Breast Cancer AJCC v7+3 more
Active, not recruitingInterventional · Phase 2NCT03092856 ↗Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell CarcinomaAna M. MolinaPIInterventionBiological: Anti-OX40 Antibody PF-04518600 · Drug: Axitinib · Other: Laboratory Biomarker Analysis · Other: PlaceboDatesJul 2017 – Dec 2026 (est.)SponsorUSC Keck School of Medicine Norris Cancer CenterClear Cell Renal Cell CarcinomaMetastatic Renal Cell CancerRecurrent Renal Cell Carcinoma+1 more
Active, not recruitingInterventional · Phase 1NCT03190278 ↗Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid LeukemiaGail J RobozPIInterventionBiological: UCART123v1.2DatesJun 2017 – Dec 2024SponsorCellectis, IncRelapsed/Refractory Acute Myeloid Leukemia
Active, not recruitingInterventional · Phase 1/2NCT03331198 ↗An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)Tsiporah B ShorePIInterventionBiological: JCAR017 (lisocabtagene maraleucel) · Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib · Biological: JCAR017 (lisocabtagene maraleucel) + venetoclaxDatesNov 2017 – Nov 2027 (est.)SponsorJuno Therapeutics, Inc.Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic
Active, not recruitingInterventional · Phase 2NCT03407144 ↗An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)Lisa Giulino RothPIInterventionBiological: pembrolizumab · Drug: doxorubicin · Drug: vinblastine · Drug: dacarbazine · Drug: cyclophosphamide · Drug: vincristine · Drug: prednisone/prednisolone · Drug: bleomycin · Drug: etoposide · Radiation: Radiotherapy (RT)DatesApr 2018 – Feb 2027 (est.)SponsorChildren's Oncology GroupHodgkin Lymphoma
Active, not recruitingInterventional · Phase 2/3NCT03604991 ↗A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction AdenocarcinomaManish A ShahPIInterventionProcedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Biological: Ipilimumab · Biological: Nivolumab · Drug: Paclitaxel · Procedure: Positron Emission Tomography · Radiation: Radiation TherapyDatesMay 2019 – Mar 2027 (est.)SponsorECOG-ACRIN Cancer Research GroupClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8+5 more
RecruitingInterventional · Phase 2NCT03606967 ↗Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast CancerMassimo CristofanilliPIInterventionProcedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Biological: Durvalumab · Drug: Gemcitabine Hydrochloride · Procedure: Magnetic Resonance Imaging · Drug: Nab-paclitaxel · Biological: Personalized Synthetic Long Peptide Vaccine · Drug: Poly ICLC · Biological: Sacituzumab Govitecan · Biological: TremelimumabDatesApr 2021 – Dec 2026 (est.)SponsorNational Cancer InstituteAnatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaMetastatic Triple-Negative Breast Carcinoma
RecruitingInterventional · Phase 1NCT03666000 ↗A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)Sebastian A. MayerPIInterventionBiological: Azer-cel · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: IL-2 · Drug: Ibrutinib, Acalabrutinib, Zanubrutinib, or PirtobrutinibDatesMar 2019 – Jun 2027 (est.)SponsorPrecision BioSciences, Inc.Non-Hodgkin LymphomaB-cell Acute Lymphoblastic LeukemiaChronic Lymphocytic Leukemia+1 more
Active, not recruitingInterventional · Phase 2NCT03712202 ↗A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)Jia RuanPIInterventionDrug: Bleomycin · Drug: Brentuximab Vedotin · Drug: Dacarbazine · Drug: Doxorubicin · Biological: Nivolumab · Other: Quality-of-Life Assessment · Drug: VinblastineDatesNov 2018 – Nov 2024· Results postedSponsorCity of Hope National Medical CenterAnn Arbor Stage I Hodgkin LymphomaAnn Arbor Stage I Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma+11 more
Active, not recruitingInterventional · Phase 3NCT03725059 ↗A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)Eleni AndreopoulouPIInterventionBiological: Pembrolizumab (K) · Drug: Placebo (P) · Drug: Paclitaxel (X) · Drug: Doxorubicin (A) · Drug: Epirubicin (E) · Drug: Cyclophosphamide (C) · Drug: Endocrine therapy · Radiation: Radiation therapy · Procedure: SurgeryDatesDec 2018 – Jan 2031 (est.)SponsorMerck & Co., Inc.Breast Cancer
Active, not recruitingInterventional · Phase 3NCT03737981 ↗A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)John AllanPIInterventionDrug: Ibrutinib · Biological: Obinutuzumab · Other: Observation Activity · Drug: VenetoclaxDatesJan 2019 – Jan 2025· Results postedSponsorAlliance for Clinical Trials in OncologyChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
RecruitingInterventional · Phase 2NCT03739814 ↗A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory DiseaseEllen K. RitchiePIInterventionProcedure: Biospecimen Collection · Biological: Blinatumomab · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Biological: Inotuzumab Ozogamicin · Procedure: Lumbar Puncture · Drug: PonatinibDatesMay 2019 – Feb 2027 (est.)SponsorAlliance for Clinical Trials in OncologyB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
Active, not recruitingInterventional · Phase 3NCT03765918 ↗A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)Doru PaulPIInterventionBiological: Pembrolizumab 200 mg · Radiation: Radiotherapy 60 Gray · Radiation: Radiotherapy 66 Gray · Radiation: Radiotherapy 70 Gray · Drug: Cisplatin 100 mg/m^2DatesDec 2018 – Jul 2024· Results postedSponsorMerck Sharp & Dohme CorpHead and Neck Neoplasms
Active, not recruitingInterventional · Phase 2NCT03767348 ↗An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]Anna C PavlickPIInterventionBiological: RP1 · Biological: nivolumabDatesSep 2017 – Jun 2028 (est.)SponsorReplimune Inc.Non-Small Cell Lung Cancer (NSCLC)Microsatellite Instability-High (MSI-H)Non-melanoma Skin Cancer (NMSC)+1 more
Active, not recruitingInterventional · Phase 3NCT03793166 ↗PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]Ana M. MolinaPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabozantinib · Procedure: Computed Tomography · Biological: Ipilimumab · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Other: Quality-of-Life Assessment · Other: Questionnaire AdministrationDatesJun 2019 – Mar 2028 (est.)SponsorAlliance for Clinical Trials in OncologyClear Cell Renal Cell CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Lymph Nodes+6 more
RecruitingInterventional · Phase 2NCT03804944 ↗Converting HR+ Breast Cancer Into an Individualized VaccineSilvia Chiara FormentiPIInterventionRadiation: Focal Radiation therapy · Drug: Pembrolizumab (200mg IV for 30 minutes · Biological: CDX-301DatesMar 2020 – Dec 2026 (est.)SponsorWeill Medical College of Cornell UniversityBreast Cancer
Active, not recruitingInterventional · Phase 3NCT03811015 ↗A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCCHani Lamie AshamallaPIInterventionProcedure: Biospecimen Collection · Drug: Cisplatin · Procedure: Computed Tomography · Procedure: Echocardiography Test · Other: Fludeoxyglucose F-18 · Radiation: Intensity-Modulated Radiation Therapy · Biological: Nivolumab · Other: Patient Observation · Procedure: Positron Emission TomographyDatesAug 2019 – Jan 2030 (est.)SponsorECOG-ACRIN Cancer Research GroupClinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
RecruitingInterventional · Phase 1NCT03816345 ↗A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)Ashish SaxenaPIInterventionProcedure: Biospecimen Collection · Drug: Cabozantinib · Drug: Fluoropyrimidine · Biological: Ipilimumab · Biological: Nivolumab · Drug: Platinum Compound · Drug: Platinum DoubletDatesJul 2019 – Mar 2028 (est.)SponsorNational Cancer InstituteAutoimmune DiseaseCrohn DiseaseDermatomyositis+11 more